Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Long-term use of ticagrelor in patients with prior myocardial infarction.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.

N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

2.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators.

Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.

3.

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.

McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagener G, Chasan-Taber S.

PLoS One. 2012;7(11):e49006. doi: 10.1371/journal.pone.0049006. Epub 2012 Nov 13.

4.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
5.

Patient retention gifts in clinical trials - undue inducement or justified motivational tools?

Burgess LJ, Sulzer N.

S Afr Med J. 2011 Sep 5;101(9):640-1.

PMID:
21920155
6.

Primary prevention of atherosclerotic vascular disease.

Burgess LJ, Sulzer NU.

SADJ. 2010 Aug;65(7):316-9. Review. No abstract available.

PMID:
21133234
7.

The growing disparity between clinical trial complexity and investigator compensation.

Burgess LJ, Sulzer NU.

Cardiovasc J Afr. 2010 Sep-Oct;21(5):249-50. No abstract available.

8.

Clinical trials in South Africa: Need for capacity building and training.

Burgess LJ, Sulzer NU.

S Afr Med J. 2010 Jul 2;100(7):402. No abstract available.

PMID:
20822581
9.

Potential for medical error: incorrectly completed request forms for thyroid function tests limit pathologists' advice to clinicians.

Zemlin AE, Nutt L, Burgess LJ, Eiman F, Erasmus RT.

S Afr Med J. 2009 Sep;99(9):668-71.

PMID:
20073294
10.

Patients' motivations for participating in cardiovascular clinical trials: a local perspective.

Burgess LJ, Sulzer NU, Hoosain F, Leverton N, Bliganut S, Emanuel S.

Cardiovasc J Afr. 2009 Jul-Aug;20(4):220-3.

11.

Two cases of severe hypoalbuminemia (<10 g/L).

Zemlin AE, Burgess LJ, Engelbrecht A.

Nutrition. 2009 Oct;25(10):1006-10. doi: 10.1016/j.nut.2008.12.017. Epub 2009 May 31.

PMID:
19487103
12.

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.

Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, Nosworthy AL, Werner ID, Raats J, Burgess LJ.

Cancer Chemother Pharmacol. 2009 Sep;64(4):763-8. doi: 10.1007/s00280-009-0925-9. Epub 2009 Feb 25.

PMID:
19241078
13.

The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions.

Zemlin AE, Burgess LJ, Carstens ME.

Int J Tuberc Lung Dis. 2009 Feb;13(2):214-20.

PMID:
19146750
14.

The management of tuberculous pericardial effusion: experience in 233 consecutive patients.

Reuter H, Burgess LJ, Louw VJ, Doubell AF.

Cardiovasc J S Afr. 2007 Jan-Feb;18(1):20-5.

15.

Experience with adjunctive corticosteroids in managing tuberculous pericarditis.

Reuter H, Burgess LJ, Louw VJ, Doubell AF.

Cardiovasc J S Afr. 2006 Sep-Oct;17(5):233-8.

16.

GCP accreditation -- a worthwhile investment?

Burgess LJ, Sulzer NU.

S Afr Med J. 2006 Mar;96(3):161-2. No abstract available.

17.

The role of histopathology in establishing the diagnosis of tuberculous pericardial effusions in the presence of HIV.

Reuter H, Burgess LJ, Schneider J, Van Vuuren W, Doubell AF.

Histopathology. 2006 Feb;48(3):295-302.

PMID:
16430476
18.

Characterization of the immunological features of tuberculous pericardial effusions in HIV positive and HIV negative patients in contrast with non-tuberculous effusions.

Reuter H, Burgess LJ, Carstens ME, Doubell AF.

Tuberculosis (Edinb). 2006 Mar;86(2):125-33. Epub 2005 Dec 19.

PMID:
16360340
19.

Tuberculous pericarditis.

Mayosi BM, Burgess LJ, Doubell AF.

Circulation. 2005 Dec 6;112(23):3608-16. Review.

20.

Pseudohyponatraemia in a patient with obstructive jaundice.

le Riche M, Burgess LJ, Marais AD.

Clin Chim Acta. 2006 Apr;366(1-2):357-60. Epub 2005 Nov 14.

PMID:
16289427
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk